Truist downgraded Longboard Pharmaceuticals to Hold from Buy with an unchanged price target of $60 after Lundbeck agreed to acquire the company for $60 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Longboard Pharmaceuticals downgraded to Neutral from Outperform at Baird
- M&A News: Lundbeck to Acquire Longboard (NASDAQ:LBPH) for $2.6B
- Boeing to cut 10% of workforce, Lundbeck to acquire Longboard: Morning Buzz
- Longboard Pharmaceuticals downgraded to Neutral from Outperform at Wedbush
- Longboard Pharmaceuticals deal comes earlier than expected, says Truist